Discovery & history
In 1973, a doctoral student at UCSF noticed that old human liver cells behaved young after a bath in young blood serum.…
The tripeptide that ties copper to skin and wound biology
In 1973, a doctoral student at UCSF noticed that old human liver cells behaved young after a bath in young blood serum. Loren Pickart spent four years isolating the active component and showed it was a tripeptide bound to copper, glycyl-L-histidyl-L-lysine, or GHK.
This unit traces that discovery, defines the key terms, and sets the honest evidence picture: solid in skin and cell culture, moderate in wounds, and thin for broad systemic anti-aging in humans.
What you'll learn
- How GHK-Cu was discovered in 1973 and what it actually is
- The copper-carrier and cuproenzyme mechanisms behind its repair reputation
- How to read the skin, hair, wound, and gene-expression evidence tier by tier
- How to think critically about delivery, dosing claims, and copper safety
What this course covers
12 units take you from the essentials to specialist-level mastery.
- 01 Discovery & history The tripeptide that ties copper to skin and wound biology free
- 02 The molecule and its copper chelate Three amino acids that grip a single copper ion paid
- 03 How it works: the copper-carrier model Delivering copper to the enzymes that build and protect tissue paid
- 04 How it works: inflammation and matrix remodeling Tuning inflammation and rebuilding the matrix paid
- 05 The gene-expression data The "resets gene expression" data, read carefully paid
- 06 Skin and cosmetic evidence The strongest human evidence GHK-Cu has paid
- 07 Hair-growth signals A weaker hair story than the marketing suggests paid
- 08 Wound healing Moderate evidence, from one human trial and many animals paid
- 09 Delivery, dosing & administration How GHK-Cu is prepared and administered paid
- 10 The research frontier Where GHK-Cu is being studied next paid
- 11 Safety & side effects What we know about GHK-Cu safety, and what we do not paid
- 12 Final exam & certification Pass the final exam to earn your specialist certificate. exam
Key terms
Young serum, old cells
Pickart’s pivotal experiment was elegantly simple: he bathed old human liver cells in serum from young donors and watched what changed. Liver tissue from donors aged 60 to 80 carried an elevated fibrinogen signature, and that pattern reverted toward youth in young serum.
Nothing was added to the old cells except young serum, so whatever caused the change had to be a substance already circulating in young blood and fading with age. That single inference turned a curious observation into a four-year hunt for one molecule.
This was a laboratory experiment, not a clinical treatment. The effect was seen in isolated cells, not living people.
Key milestones
Half a century separates the discovery from today’s reviews, and the popular hype consistently ran years ahead of the evidence. These are the major beats, from isolation to the modern gene-expression work.
What stands out is how slowly the real picture filled in. The 1980s work showed GHK-Cu could stimulate collagen synthesis, but only in the 2010s did large reviews pull the scattered cell, animal, and small human studies together into one story.
AdvancedWhy the early dates are fuzzy
The 1973 date marks the observation; isolation and sequence identification took until about 1977, and the copper-tripeptide name was applied later. Sources differ on which year to cite because they anchor on different steps of the same multi-year effort.
What GHK-Cu actually is
Strip away the hype and GHK-Cu is just three amino acids in a row, carrying a single copper ion. It occurs naturally in human plasma, and its level falls steadily as we age, which is a big part of why interest centers on replacing it.
Those three residues explain why GHK-Cu behaves so differently from a plain copper salt: the histidine grips the copper while glycine and lysine shape a stable, skin-penetrating pocket. Take the copper away and the bare peptide still signals, but copper is what most of its repair effects depend on.
AdvancedHow the age-related decline is measured
The fall is tracked directly, because GHK circulates in plasma: roughly 200 ng/mL in young adults drops to about 80 ng/mL by later life, a decline of around 60%. That curve is the engine of the replacement idea, though a level that drops with age is a correlation, not proof that topping it up reverses anything.
The honest evidence ceiling
Before any mechanisms, the honest picture: what is actually well supported versus merely hopeful. Keeping these tiers apart is the whole point of this course, because the marketing tends to round everything up to proven. The pattern repeats at every level: a real but modest finding in cells or a small study gets restated online as a settled human result. Sorting each claim into solid, moderate, weak, or missing is the habit this page is training.
AdvancedWhat "well supported" actually requires
The tiers are really a hierarchy of evidence type: a controlled human trial outweighs an animal study, which outweighs a cell-culture or gene-expression result. GHK-Cu has solid footing only where that hierarchy reaches small human trials, which is essentially topical skin, so most other claims sit a tier or two lower than the marketing implies.
This course is education, not medical advice. Nothing here is a recommendation to use GHK-Cu.
Popular claims, checked
A few specific claims you will see online, held against the evidence above. Notice the pattern: most are not flatly false, they are real but modest findings rounded up into certainty.
Reading each claim against its actual evidence tier is exactly the skill this course is built to give you. By the final exam, you should be able to take any GHK-Cu marketing sentence and place it on this map yourself.
Where the body’s own GHK comes from
GHK is not foreign to the body. It circulates in plasma and is also liberated when certain matrix proteins break down, which is why researchers describe it as a natural signal that injury releases on site.
This framing matters: if GHK is a repair signal the body makes less of over time, then supplying it is conceptually replacement rather than adding something alien. That logic is appealing, but it is a rationale for studying GHK-Cu, not proof that topping it up restores youthful repair in people.
AdvancedWhy "released on injury" is suggestive
The SPARC finding is attractive because it places GHK exactly where repair is needed, at the moment matrix is damaged. It is a strong mechanistic story, but a story about where a molecule appears is not the same as a measured clinical benefit, which is the distinction this course keeps returning to.